I-Mab

NasdaqGM:IMAB Stock Report

Market Cap: US$77.6m

I-Mab Valuation

Is IMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMAB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMAB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMAB?

Key metric: As IMAB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for IMAB. This is calculated by dividing IMAB's market cap by their current revenue.
What is IMAB's PS Ratio?
PS Ratio24.1x
SalesUS$3.31m
Market CapUS$77.61m

Price to Sales Ratio vs Peers

How does IMAB's PS Ratio compare to its peers?

The above table shows the PS ratio for IMAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average29.5x
CBUS Cibus
25.3x64.6%US$128.3m
VTVT vTv Therapeutics
37.6xn/aUS$49.5m
STTK Shattuck Labs
8.2x-79.8%US$54.4m
FIXX Homology Medicines
47xn/aUS$54.3m
IMAB I-Mab
24.1x53.4%US$77.6m

Price-To-Sales vs Peers: IMAB is good value based on its Price-To-Sales Ratio (24.1x) compared to the peer average (29.5x).

Price to Sales Ratio vs Industry

How does IMAB's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
3.9x2.4%US$109.25b
BIIB Biogen
2.4x1.3%US$22.65b
MRNA Moderna
2.8x7.2%US$14.35b
INCY Incyte
3.4x8.9%US$13.59b
IMAB 24.1xIndustry Avg. 10.1xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: IMAB is expensive based on its Price-To-Sales Ratio (24.1x) compared to the US Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is IMAB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMAB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio24.1x
Fair PS Ratio13.1x

Price-To-Sales vs Fair Ratio: IMAB is expensive based on its Price-To-Sales Ratio (24.1x) compared to the estimated Fair Price-To-Sales Ratio (13.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IMAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.98
US$6.75
+588.8%
19.2%US$8.00US$5.00n/a4
Nov ’25US$1.07
US$6.75
+530.8%
19.2%US$8.00US$5.00n/a4
Oct ’25US$1.22
US$6.75
+453.3%
19.2%US$8.00US$5.00n/a4
Sep ’25US$1.13
US$6.75
+497.3%
19.2%US$8.00US$5.00n/a4
Aug ’25US$1.31
US$7.25
+453.4%
26.5%US$10.00US$5.00n/a4
Jul ’25US$1.62
US$7.25
+347.5%
26.5%US$10.00US$5.00n/a4
Jun ’25US$1.66
US$7.25
+336.7%
26.5%US$10.00US$5.00n/a4
May ’25US$1.77
US$7.25
+310.8%
26.5%US$10.00US$5.00n/a4
Apr ’25US$1.81
US$7.25
+300.6%
26.5%US$10.00US$5.00n/a4
Mar ’25US$1.79
US$11.50
+542.5%
45.4%US$18.00US$5.00n/a4
Feb ’25US$1.82
US$21.56
+1,084.3%
23.9%US$30.33US$15.00n/a6
Jan ’25US$1.90
US$21.56
+1,034.5%
23.9%US$30.33US$15.00n/a6
Dec ’24US$1.63
US$25.68
+1,475.2%
43.5%US$50.40US$15.00n/a7
Nov ’24US$1.53
US$25.68
+1,578.2%
43.5%US$50.40US$15.00US$1.077
Oct ’24US$1.32
US$25.68
+1,845.1%
43.5%US$50.40US$15.00US$1.227
Sep ’24US$1.94
US$23.59
+1,116.0%
50.7%US$50.40US$8.00US$1.138
Aug ’24US$2.77
US$30.03
+984.2%
50.3%US$64.60US$8.00US$1.3110
Jul ’24US$2.99
US$30.03
+904.4%
50.3%US$64.60US$8.00US$1.6210
Jun ’24US$3.03
US$27.65
+812.5%
58.8%US$64.60US$3.80US$1.6611
May ’24US$3.15
US$25.37
+705.5%
60.3%US$64.60US$3.80US$1.7710
Apr ’24US$3.46
US$32.22
+831.3%
50.4%US$64.60US$3.80US$1.8112
Mar ’24US$4.31
US$33.57
+678.8%
45.8%US$64.60US$3.80US$1.7913
Feb ’24US$6.31
US$35.88
+468.7%
47.4%US$66.00US$3.80US$1.8214
Jan ’24US$4.18
US$36.38
+770.4%
44.8%US$66.00US$3.80US$1.9014
Dec ’23US$3.69
US$36.38
+886.0%
44.8%US$66.00US$3.80US$1.6314
Nov ’23US$3.90
US$38.89
+897.2%
36.2%US$66.00US$16.00US$1.5313

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%